Steevenson Nelson
About Steevenson Nelson
Steevenson Nelson is a postdoctoral researcher with expertise in virology, focusing on the mechanisms of alpha- and flavivirus lifecycles. He has a strong background in molecular biology and tissue culture, and possesses BSL3 training for handling high-risk pathogens.
Work at National Institutes of Health
Steevenson Nelson has a long-standing association with the National Institutes of Health (NIH). He began his tenure there as a Ph.D. student at the Laboratory of Viral Diseases from 2005 to 2010, where he focused on viral research. After completing his doctorate, he continued at NIH as a Postdoctoral researcher, a position he has held since 2005. His work involves advanced research in virology, particularly concerning alpha- and flavivirus lifecycles.
Education and Expertise
Steevenson Nelson earned his Ph.D. in Biochemistry from North Carolina State University, where he studied from 2001 to 2005. His educational background provides a strong foundation in molecular biology and virology. He possesses BSL3 training, which signifies his capability to work with high-risk pathogens in a controlled laboratory setting. His expertise extends to tissue culture and the production of immunologically relevant targets for structural studies.
Background
Before his time at the NIH, Steevenson Nelson was a Graduate Student at North Carolina State University from 2001 to 2005. His academic journey laid the groundwork for his research interests and expertise in virology. His experience at both institutions has contributed to his understanding of viral mechanisms and the development of subunit vaccines.
Research Focus
Steevenson Nelson's current research focuses on understanding the mechanisms of alpha- and flavivirus lifecycles. He has extensive experience in the production of immunologically relevant targets, which are crucial for structural studies. His work also includes subunit vaccine production and antibody-mediated particle neutralization, contributing to advancements in virology and vaccine development.